Secure your molecule's future.
Act now.
In a world of change, you need a trusted global partner with a strong US presence to progress your molecule. Our proven track record and deep experience help protect your molecule, however complex, whatever the phase.
Flexible terms allow us to tailor our program around your clinical, commercial and financial milestones. With a dedicated team of global experts to provide continuous support and stability at every step of the journey, you know you’re in safe hands.
Over 60% of our customers are small biotech companies
Over 25 years of
biologics experience
Pre-clinical to commercial molecule progression
3 reasons to partner with us
- Proven Track Record & Expertise
- 150 successful tech transfers
- 100% Success rate for IND & BLA-enabling CMC dossiers
- Over 440 mammalian molecules supported across the life cycle in 2023
- Expertise with various CCO cell lines, including CHO-K1
- Global Network & Capacity
- Global player on three continents with a strong US presence
- Manufacturing network spanning from 1kL to 20kL — seamless and fast scale-up to meet your evolving needs
- High process flexibility to address your project-specific requirements
- Minimizing your COGS through operational efficiency, high-titer processing, advanced N-1 perfusion programs
- Customer-Centric Services
- Flexibility in production schedule and the capacity to adapt to changing market conditions
- Flexible commercial and manufacturing terms to help enable the advancement of your molecule from pre-clinical to commercial
Shaped around your journey: Hear from companies who chose to partner with us
“We are a small company and demands on our time meant we had to delay the start of the tech transfer into the Slough facility. Lonza was accommodating and reworked the schedule twice.
This was refreshing, as we have experienced CDMOs who are unable to shift the schedule.”
Julie Trulson, Ph.D. Vice President and Head of CMC, Asher Biotherapeutics
“Lonza’s brand name is a crucial factor that is particularly valuable for smaller biotechs, it lends credibility and provides comfort to investors and regulators that high-quality antibody skills will be implemented.
Lonza helped us understand the biggest risks and how they could be managed. That openness has been invaluable.”
William B. Jones, Ph.D., Senior Vice President of Pharmaceutical Development, Corvus Pharmaceutical
Ready to learn more? Get in touch for a personal consultation.
Lonza can support your manufacturing needs from early development to commercialization. For more information, please visit our website.
